Clinical Trial Update: Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ropinirole prolonged-release as an adjunct to levodopa in advanced Parkinson disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Requip XL (ropinirole extended-release) (ropinirole)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED | Results posted: 2011-10-07